Alkem Laboratories is currently trading at Rs. 5100.90, up by 89.80 points or 1.79% from its previous closing of Rs. 5011.10 on the BSE.
The scrip opened at Rs. 5011.15 and has touched a high and low of Rs. 5250.30 and Rs. 5011.15 respectively. So far 11677 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 5581.20 on 21-May-2024 and a 52 week low of Rs. 3338.60 on 26-Jun-2023.
Last one week high and low of the scrip stood at Rs. 5260.00 and Rs. 4975.00 respectively. The current market cap of the company is Rs. 60620.05 crore.
The promoters holding in the company stood at 56.74%, while Institutions and Non-Institutions held 24.74% and 18.52% respectively.
U.S Food and Drug Administration (USFDA) has issued an Establishment Inspection Report (EIR) for Alkem Laboratories’ manufacturing facility located at Baddi, India. The Inspection has been classified as Voluntary Action Indicated (VAI) and has been closed accordingly.
Earlier, USFDA had concluded inspection at the company’s manufacturing facility located at Baddi, India. The said inspection conducted from March 19, 2024 to March 27, 2024. At the end of the inspection, the company has received Form 483 with ten observations. This was a GMP as well as a Pre-Approval Inspection. There is no data integrity observation.
Alkem Laboratories is a leading Indian pharmaceutical company with global operations, engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products. The company produces branded generics, generic drugs, active pharmaceutical Ingredients (APIs) and nutraceuticals, which it markets in India and International markets.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1808.50 |
Dr. Reddys Lab | 1342.45 |
Cipla | 1472.45 |
Lupin | 2147.55 |
Zydus Lifesciences | 973.90 |
View more.. |